<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583020</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2522</org_study_id>
    <nct_id>NCT04583020</nct_id>
  </id_info>
  <brief_title>Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma: A Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the safety and efficacy of Camrelizumab treating&#xD;
      patients with newly diagnosed glioblastomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II clinical trial. The purpose of this research is to study the safety and&#xD;
      efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas. Neoadjuvant&#xD;
      PD-1 inhibitor will be administered to patients with newly diagnosed glioblastomas, followed&#xD;
      by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Neoadjuvant PD-1 inhibitor will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Survival will be assessed at 6 months and 12 months from the time of recruitment until the time of death. Kaplan-Meier survival analyses will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Progression-free survival will be assessed at 6 months and 12 months from the time of recruitment until the time of death. Kaplan-Meier survival analyses will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment-related adverse events</measure>
    <time_frame>up to 2 years</time_frame>
    <description>toxicity assessed by Common Toxicity Criteria (CTC) version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>response rate assessed by Response Assessment in Neuro-Oncology (RANO) criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant PD-1 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant PD-1 inhibitor Camrelizumab will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)</description>
    <arm_group_label>Neoadjuvant PD-1 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>60Gy/30</description>
    <arm_group_label>Neoadjuvant PD-1 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles</description>
    <arm_group_label>Neoadjuvant PD-1 inhibitor</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be willing to provide informed consent.&#xD;
&#xD;
          2. Patient must be 18-70 years old.&#xD;
&#xD;
          3. Patient must be first diagnosed of WHO grade IV neural glioma by MRI, without previous&#xD;
             treatment.&#xD;
&#xD;
          4. Patient must receive confine operation that can be delayed for at least 2 weeks, in&#xD;
             order to receive neoadjuvant treatment; patient must not receive other antitumor&#xD;
             therapy besides this study plan.&#xD;
&#xD;
          5. Karnofsky ≥ 70&#xD;
&#xD;
          6. If patient is on glucocorticoids treatment, the amount of glucocorticoids must be&#xD;
             stable or decreasing at least 5 days before baseline MRI acquisition. Oral&#xD;
             dexamethasone must be &lt;3 tablets(0.75mg/tablet) at least 5 days before baseline MRI.&#xD;
&#xD;
          7. Patient has not received antibiotics for 1month before inclusion.&#xD;
&#xD;
          8. Estimate survival ≥12weeks.&#xD;
&#xD;
          9. Major organ functions normally, without severe blood, heart, lung, liver, renal&#xD;
             abnormality or immune deficiency. Laboratory examination meets the following&#xD;
             requirements:&#xD;
&#xD;
             i. Complete blood count:&#xD;
&#xD;
               1. HGB≥90g/L;&#xD;
&#xD;
               2. WBC≥3.0×109/L, NEUT≥1.5×109/L;&#xD;
&#xD;
               3. PLT ≥60×109/L;&#xD;
&#xD;
             ii. Blood biochemistry:&#xD;
&#xD;
               1. BIL≤1.5×upper limit of normal (ULN);&#xD;
&#xD;
               2. ALT and AST≤2.0×ULN;&#xD;
&#xD;
               3. Serum Cr≤1.5×ULN or Ccr≥50ml/min (Cockcroft-Gault formular);&#xD;
&#xD;
             iii. Fecal occult blood(-);&#xD;
&#xD;
             iv. Urine routines normal, or urine protein &lt;(++), or 24h urine protein&lt;1.0g;&#xD;
&#xD;
             v. Left ventricular ejection fraction(LVEF)≥50%.&#xD;
&#xD;
         10. Normal clotting function, no active bleeding or thrombosis disease.&#xD;
&#xD;
               1. INR≤1.5×ULN;&#xD;
&#xD;
               2. APTT≤1.5×ULN;&#xD;
&#xD;
               3. PT≤1.5ULN;&#xD;
&#xD;
         11. Female patients of childbearing potential must receive pregnancy test (serum or urine)&#xD;
             with negative result, and voluntarily practice appropriate forms of contraception,&#xD;
             during observation period and 8 weeks after final administration of Camrelizumab; male&#xD;
             patients should receive surgical sterilization or agree to practice appropriate forms&#xD;
             of contraception, during observation period and 8 weeks after final administration of&#xD;
             Camrelizumab.&#xD;
&#xD;
         12. Patient should have good follow-up compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with other malignant tumor history in five years (except complete treatment of&#xD;
             cervical cancer in situ, basal cell carcinoma, squamous cell skin cancer).&#xD;
&#xD;
          2. Patient needs emergency surgery.&#xD;
&#xD;
          3. History of allergy to other monoclonal antibody or other ingredients; or can not&#xD;
             receive MRI.&#xD;
&#xD;
          4. Previous immunotherapy (e.g. PD-1, PD-L1, CTLA-4), previous intracranial radiotherapy.&#xD;
&#xD;
          5. Any previous investigational medication within 4 weeks before first administration of&#xD;
             Camrelizumab.&#xD;
&#xD;
          6. Included in another clinical investigation simultaneously, except for observational&#xD;
             (non-interventional) clinical study or follow-up of an interventional clinical study.&#xD;
&#xD;
          7. Already has meningioma, multiple gliomas, extracranial lesions. The definition of&#xD;
             multiple gliomas is: discontinuous strong signal on T2/FLAIR; satellite lesions.&#xD;
&#xD;
          8. History of antitumor vaccine injection, or history of live vaccine injection within 4&#xD;
             weeks before first administration of Camrelizumab.&#xD;
&#xD;
          9. Less than 4 weeks after the latest surgery, radiochemotherapy, glucocorticoids&#xD;
             treatment, immunotherapy, targeted therapy.&#xD;
&#xD;
         10. Thrombosis event within 12 months before inclusion, such as cerebrovascular accident&#xD;
             (TIA, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary&#xD;
             embolism.&#xD;
&#xD;
         11. Any unstable systematic disease (including active infection, uncontrolled&#xD;
             hypertension, unstable angina, medical treatment needed liver, kidney, metabolic&#xD;
             disease).&#xD;
&#xD;
         12. Heart failure with NYHA grade 2 or above, unstable angina, myocardial infarction&#xD;
             within 1 year, treatment needed supraventricular or ventricular arrhythmia.&#xD;
&#xD;
         13. Patient with known HIV infection or active hepatitis.&#xD;
&#xD;
         14. History or risk of autoimmune disease, such as systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis. Patient is&#xD;
             allowed to be included, if eczema, psoriasis or leukoderma is well controlled at&#xD;
             baseline, with only local weak steroid treatment.&#xD;
&#xD;
         15. Systematic immune suppressor, such as prednisone, cyclophosphamide, amethopterin,&#xD;
             azathioprim, thalidomide, anti-TNF drugs. Low dose of systematic immune suppressor is&#xD;
             allowed (e.g. single dose of dexamethasone for nausea). Patient with postural&#xD;
             hypotension or adrenocortical insufficiency is allowed to use inhaled corticosteroids&#xD;
             and mineralocorticoid.&#xD;
&#xD;
         16. History of interstitial lung disease, idiopathic pulmonary fibrosis, pneumonia, tissue&#xD;
             pneumonia, or evidence of active pneumonia on CT scan. Radiation pneumonia or&#xD;
             pulmonary fibrosis is allowed in patient with radiation history.&#xD;
&#xD;
         17. Other chronic disease that requires immune suppressor or corticosteroids treatment.&#xD;
&#xD;
         18. Female patients who are pregnant or currently breastfeeding.&#xD;
&#xD;
         19. Active infection or fever of unknown origin &gt;38.5℃ at the first administration of&#xD;
             Camrelizumab.&#xD;
&#xD;
         20. Blood clotting abnormality, bleeding tendency or receiving thrombolytic or&#xD;
             anticoagulant therapy.&#xD;
&#xD;
         21. Patient with known history of Psychotropic drug abuse, alcoholism or drug addiction.&#xD;
&#xD;
         22. Other situation determined by the researcher that may influence the conduction or&#xD;
             result of the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Wang, MD</last_name>
    <phone>861069152530</phone>
    <email>ywang@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Camrelizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no IPD share plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

